Provided by Tiger Trade Technology Pte. Ltd.

INNOVENT BIO

90.750
+1.6501.85%
Volume:5.74M
Turnover:521.67M
Market Cap:157.45B
PE:-1.33K
High:91.500
Open:89.900
Low:89.900
Close:89.100
52wk High:109.100
52wk Low:36.600
Shares:1.74B
HK Float Shares:1.74B
Volume Ratio:0.47
T/O Rate:0.33%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.068
ROE:8.43%
ROA:2.65%
PB:9.64
PE(LYR):-1,334.97
PS:12.17

Loading ...

A Look At Innovent Biologics (SEHK:1801) Valuation After Progress In Phase 3 IBI354 Breast Cancer Trial

Simply Wall St.
·
Feb 17

Innovent Biologics Doses First Patient in Phase 3 Trial of Novel HER2 ADC for Advanced Breast Cancer

Reuters
·
Feb 13

JPMorgan Increases Stake in Innovent Bio by 585,900 Shares at HK$79.23 Each

Stock News
·
Feb 12

Innovent Biologics Forges Seventh Partnership with Eli Lilly in $8.85 Billion Deal

Deep News
·
Feb 10

Innovent Appears on Track to Meet 2027 Revenue Target -- Market Talk

Dow Jones
·
Feb 10

INNOVENT BIO Shares Climb Over 5% Again Following Seventh Global Partnership with Eli Lilly; Goldman Sachs Sees Undervaluation

Stock News
·
Feb 10

Asian Market Stocks Trading Below Estimated Value In February 2026

Simply Wall St.
·
Feb 10

Hong Kong Stocks Rebound Strongly During Window Period as New AI Models Provide Positive Boost

Stock News
·
Feb 09

Innovent, Pop Mart Lead Hang Seng Index Higher -- Market Talk

Dow Jones
·
Feb 09

Bank of America Securities Reaffirms "Buy" Rating on Innovent Biologics with HK$113.5 Target Price

Stock News
·
Feb 09

CICC Maintains Outperform Rating on Innovent Biologics with HK$118.3 Target Price

Stock News
·
Feb 09

INNOVENT BIO Shares Surge Over 4% on Strategic Collaboration with Eli Lilly Potentially Worth $8.85 Billion

Stock News
·
Feb 09

INNOVENT BIO and Eli Lilly Form Global Strategic Alliance to Advance Oncology and Immunology Drug Development

Stock News
·
Feb 08

Innovent (1801) Announces Seventh Collaboration with Lilly to Develop Global Oncology and Immunology Medicines

Bulletin Express
·
Feb 08

Innovent Announces Strategic Collaboration With Lilly To Develop New Medicines Globally In Oncology And Immunology

Reuters
·
Feb 08

Innovent Biologics and Eli Lilly Announce Global Oncology and Immunology Collaboration

Reuters
·
Feb 08

Innovent Announces Strategic Collaboration With Lilly to Develop New Medicines Globally in Oncology and Immunology

THOMSON REUTERS
·
Feb 08

Innovent Biologics: Is Eligible to Receive Development, Regulatory & Commercial Milestone Payments up to Est $8.5 Bln Contingen Certain Future Events

THOMSON REUTERS
·
Feb 08

Innovent Biologics - Innovent Will Receive a $350 Mln Upfront Payment

THOMSON REUTERS
·
Feb 08

JPMorgan Boosts Stake in Innovent Bio by Approximately 1.23 Million Shares at HK$78.70 Each

Stock News
·
Feb 06